Actively Recruiting
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
Led by Fudan University · Updated on 2026-04-21
150
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.
CONDITIONS
Official Title
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at study entry
- Barcelona Clinic Liver Cancer stage C or stage B not suitable for curative or locoregional treatments
- Hepatocellular carcinoma confirmed by imaging, tissue analysis, or cell study
- No prior systemic treatment for hepatocellular carcinoma
- At least one measurable tumor site by CT or MRI scan according to RECIST1.1 criteria
- Child-Pugh liver function score between 5 and 7, and performance status 0 to 2 on ECOG scale
- Adequate organ function including specific blood counts, liver enzymes, and kidney function
- Willingness to provide tumor tissue samples and blood samples
- Signed informed consent
You will not qualify if you...
- Previous systemic therapy for hepatocellular carcinoma
- Active autoimmune diseases needing immunosuppressive drugs
- Active infections that require intravenous antibiotics
- HIV positive or active hepatitis B or C infection with specific viral load thresholds
- Symptomatic brain metastases
- Pregnancy or breastfeeding
- Any condition that may prevent following the study protocol or affect data accuracy as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
P
Peng Wang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here